To mitigate the potential variability introduced by chronic immune activation in COVID-19 patients, it is critical to consider that the putative administration of low-dose IL-2 in COVID-19 patients should be restricted to the convalescent phase of the disease, long after the acute inflammation has been resolved, to avoid unwanted hyperactivation of the immune response during the acute phase of the disease. The gene discussed is IL2; the disease is COVID-19.